Practitioner Information

Maintrac® CTC Test

The Maintrac® CTC Count test is a simple blood test which finds every Circulating Tumour Cell present in the blood. CTCs in a 15-20mL sample of patient blood are detected and quantified. Live cells are distinguished from fragmented tumour cells and analysed. CTC-count is an independent prognostic indicator, that is, it gives an indication of the aggressiveness of a patient's cancer at the time of the test. A single CTC count test is intended as a simple baseline count. The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs for your clinic are available upon request by phoning 1300 282 482.

Medical director Dr. Joachim Fluhrer is available for expert consultation with medical and healthcare practitioners to discuss test selection and result interpretation.


Australia: $720
New Zealand: $820

Pricing is in AUD and subject to change without notice.

Additional tests:
Customised Chemosensitivity
Companion Diagnostics
Tumour Sphere Units


Complete instructions for ordering a test, blood sample collection and dispatch can be found here

Tests can only be ordered by registered, certified Healthcare Practitioners.

To order, please download and complete a test request, and send it to Genostics via email ( or fax (+61 2 8088 7097).

Further reading...

Maintrac Practitioner Information

Newly added publication: Behaviour of Circulating Epithelial Tumor Cells (CETCs) and FISH (Fluorescence In Situ Hybridization) of Epidermal Growth Factor Receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy ...Read this publication

Publication: Epithelial cell dissemination and readhesion: Analysis of factors contributing to metastasis formation in breast cancer (2012) ...Read this publication

Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication

Publication: Monitoring Circulating Epithelial Tumour Cells (CETC) to gauge therapy: in patients with disease progression after Tratsuzumab persisting CETC can be eliminated by combined lapatinib treatment (2008) ...Read this publication

Publication: Assessing the efficacy of targeted therapy using Circulating Epithelial Tumor Cells (CETCs): the example of SERM therapy monitoring as a unique tool to individualise therapy (2010) ...Read this publication